SCENESSE - Afamelanotide -
EMEA/H/C/002548/II/0052, Orphan
Clinuvel Europe Limited, Rapporteur: Janet
Koenig, PRAC Rapporteur: Martin Huber ,
“Update of section 4.2 of the SmPC in order to
update the posology recommendations by
removing the current recommendation of a
maximum of four implants per year, based on a
literature review and analysis of safety data.
The Package Leaflet is updated accordingly. The
RMP version 9.8 has also been submitted. In
addition, the MAH took the opportunity to
introduce a minor editoria
https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-meeting-27-30-may-2024_en.pdf
- Forums
- ASX - By Stock
- CUV
- Scenesse expanding to 4+ implants annually in the EU?
Scenesse expanding to 4+ implants annually in the EU?
-
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CUV (ASX) to my watchlist
(20min delay)
|
|||||
Last
$14.98 |
Change
-0.180(1.19%) |
Mkt cap ! $750.1M |
Open | High | Low | Value | Volume |
$15.20 | $15.20 | $14.81 | $979.2K | 65.38K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1100 | $14.95 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$14.98 | 14 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1100 | 14.950 |
1 | 12 | 14.900 |
1 | 282 | 14.870 |
1 | 282 | 14.850 |
1 | 282 | 14.820 |
Price($) | Vol. | No. |
---|---|---|
14.980 | 14 | 1 |
15.040 | 382 | 2 |
15.060 | 282 | 2 |
15.090 | 282 | 1 |
15.110 | 282 | 1 |
Last trade - 16.10pm 18/09/2024 (20 minute delay) ? |
Featured News
CUV (ASX) Chart |